Skip to main content

NASDAQ:VERU - Veru Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.20
  • Forecasted Upside: 145.84 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$7.81
▲ +0.45 (6.11%)
1 month | 3 months | 12 months
Get New Veru Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VERU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VERU

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.20
▲ +145.84% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Veru in the last 3 months. The average price target is $19.20, with a high forecast of $24.00 and a low forecast of $15.00. The average price target represents a 145.84% upside from the last price of $7.81.

Buy

The current consensus among 5 investment analysts is to buy stock in Veru. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021Jefferies Financial GroupInitiated CoverageBuy$19.00N/A
i
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$19.00High
i
3/3/2021HC WainwrightLower Price TargetBuy$22.00 ➝ $21.00High
i
2/25/2021HC WainwrightLower Price TargetBuy$22.00 ➝ $21.00High
i
2/11/2021OppenheimerBoost Price Target$19.00 ➝ $24.00Low
i
2/9/2021HC WainwrightBoost Price TargetBuy$12.00 ➝ $17.00Low
i
12/16/2020OppenheimerBoost Price TargetOutperform$9.00 ➝ $19.00Low
i
12/14/2020Brookline Capital ManagementBoost Price Target$13.00 ➝ $17.00High
i
Rating by K. Raja at Brookline Capital Management
12/14/2020Cantor FitzgeraldBoost Price TargetOverweight$6.00 ➝ $15.00High
i
12/10/2020HC WainwrightBoost Price TargetBuy$6.00 ➝ $8.00High
i
Rating by Yi Chen at HC Wainwright
9/21/2020OppenheimerReiterated RatingBuy$9.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
8/14/2020Brookline Capital ManagementReiterated RatingBuyLow
i
Rating by K. Raja at Brookline Capital Management
8/14/2020OppenheimerReiterated RatingBuy$9.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/22/2020HC WainwrightReiterated RatingBuy$6.00High
i
Rating by Yi Chen at HC Wainwright
5/14/2020OppenheimerBoost Price TargetOutperform$9.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
5/6/2020HC WainwrightReiterated RatingBuy$6.00Low
i
Rating by Yi Chen at HC Wainwright
1/21/2020HC WainwrightReiterated RatingBuy ➝ Buy$4.50 ➝ $6.00High
i
Rating by Y. Chen at HC Wainwright
12/13/2019HC WainwrightReiterated RatingBuy$4.50High
i
Rating by Y. Chen at HC Wainwright
10/3/2019HC WainwrightReiterated RatingBuyLow
i
Rating by Yi Chen at HC Wainwright
8/9/2019HC WainwrightReiterated RatingBuy$4.50High
i
Rating by Yi Chen at HC Wainwright
7/29/2019Brookline Capital ManagementInitiated CoverageBuy$12.00High
i
Rating by K. Raja at Brookline Capital Management
7/1/2019Cantor FitzgeraldInitiated CoverageOverweight$6.00High
i
Rating by B. Folkes at Cantor Fitzgerald
6/27/2019HC WainwrightReiterated RatingBuy$4.50Medium
i
Rating by Yi Chen at HC Wainwright
6/5/2019HC WainwrightSet Price TargetBuy$5.00Medium
i
Rating by Yi Chen at HC Wainwright
3/20/2019CIBCInitiated CoverageOutperform ➝ Outperform$5.00High
i
3/19/2019OppenheimerInitiated CoverageOutperform$5.00 ➝ $5.00High
i
2/14/2019Maxim GroupSet Price TargetBuy$6.00Medium
i
Rating by Jason McCarthy at Maxim Group
1/23/2019HC WainwrightReiterated RatingBuy$4.50Low
i
Rating by Ram Selvaraju at HC Wainwright
12/14/2018HC WainwrightSet Price TargetBuy$5.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/13/2018HC WainwrightSet Price TargetBuy$5.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/28/2018HC WainwrightSet Price TargetBuy$5.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/27/2018Maxim GroupReiterated RatingBuy$10.00High
i
8/15/2018HC WainwrightReiterated RatingBuy$5.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/14/2018Maxim GroupReiterated RatingBuy$10.00Low
i
7/3/2018Maxim GroupInitiated CoverageBuyHigh
i
6/25/2018Dawson JamesReiterated RatingBuyMedium
i
Rating by R. Wasserman at Dawson James
5/18/2018HC WainwrightSet Price TargetBuy$5.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/10/2018HC WainwrightSet Price TargetBuy$5.00Low
i
Rating by Ram Selvaraju at HC Wainwright
3/23/2018HC WainwrightSet Price TargetBuy$5.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/6/2018HC WainwrightSet Price TargetBuy$5.00High
i
Rating by Ram Selvaraju at HC Wainwright
2/15/2018HC WainwrightSet Price TargetBuy$5.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/9/2018HC WainwrightSet Price TargetBuy$5.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
1/3/2018HC WainwrightSet Price TargetBuy$5.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/14/2017HC WainwrightSet Price TargetBuy$5.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/14/2017HC WainwrightSet Price TargetBuy$5.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/4/2017HC WainwrightReiterated RatingBuy$5.00Low
i
Rating by R. Selvaraju at HC Wainwright
7/26/2017HC WainwrightSet Price TargetBuy$5.00High
i
7/26/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$5.00High
i
(Data available from 5/9/2016 forward)
Veru logo
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.
Read More

Today's Range

Now: $7.81
$7.65
$8.14

50 Day Range

MA: $10.38
$7.36
$14.12

52 Week Range

Now: $7.81
$2.30
$24.57

Volume

1,872,751 shs

Average Volume

3,627,519 shs

Market Capitalization

$561.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Veru?

The following Wall Street sell-side analysts have issued research reports on Veru in the last twelve months: Brookline Capital Management, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for VERU.

What is the current price target for Veru?

5 Wall Street analysts have set twelve-month price targets for Veru in the last year. Their average twelve-month price target is $19.20, suggesting a possible upside of 145.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting VERU will reach $24.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $15.00 for Veru in the next year.
View the latest price targets for VERU.

What is the current consensus analyst rating for Veru?

Veru currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VERU will outperform the market and that investors should add to their positions of Veru.
View the latest ratings for VERU.

What other companies compete with Veru?

How do I contact Veru's investor relations team?

Veru's physical mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company's listed phone number is 305-509-6897 and its investor relations email address is [email protected] The official website for Veru is www.veruhealthcare.com.